PA
VINC

Perceptive Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Perceptive Advisors’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,000
Closed -$5.79M – 163
2021
Q1 		$5.79M Hold
15,000
– – 0.07% 110
2020
Q4 		$6.27M Buy
+15,000
New +$4.73M 0.07% 115

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Perceptive Advisors's VINC Position: Q2 2021 in Review

Perceptive Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2021, closing a stake of 15,000 shares — an estimated $5.79M sold.

Perceptive Advisors first reported a position in VINC in Q4 2020 and held it in 2 quarters. The position peaked at $6.27M in Q4 2020. 56 funds tracked by Wall St. Rank hold VINC as of Q2 2021.

  • Perceptive Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Perceptive Advisors sold 15,000 Vincerx Pharma, Inc. Common Stock shares in Q2 2021, an estimated $5.79M.
  • Perceptive Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Perceptive Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $6.27M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2021.

Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.